We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Pushes for More Blinding in Medtech Pivotal Trials
U.S. FDA Pushes for More Blinding in Medtech Pivotal Trials
Devicemakers seeking regulatory approval in the U.S. are strongly urged to blind patients and investigators in pivotal clinical trials, when possible, according to final guidance issued by the Food and Drug Administration.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor